As part of an international clinical trial, Jacksonville-based Mayo Clinic in Florida has become the first U.S. site to target metastatic breast cancer with the radiopharmaceutical actinium-225.
The trial drug, which contains actinium-225, was developed to treat a subtype of gastroenteropancreatic neuroendocrine tumors. It is designed to “stick” to cancer cells as it delivers radiation without harming healthy cells, according to an Aug. 1 news release from the health system.
Mayo Clinic’s academic centers in Rochester, Minn., Phoenix and Jacksonville are participating in the trial, alongside 20 other sites across the U.S.
